a Department of Internal Medicine , University of Kansas Medical Center , Kansas City , MO , USA.
b Department of Medicine , Dow University of Health Sciences , Karachi , Pakistan.
Curr Med Res Opin. 2019 Mar;35(3):473-478. doi: 10.1080/03007995.2018.1487389. Epub 2018 Jul 5.
Clostridium difficile infection (CDI) is a significant health burden, now recognized as the leading cause of acquired diarrhea in patients receiving antibiotic therapy. Complications of infection with this pathogen include severe diarrhea, causing electrolyte imbalances, dehydration, hemodynamic instability, toxic megacolon, shock, and death. Hence it is extremely paramount to stay updated on management options for this infection, especially in cancer patients.
This article presents an in-depth review of literature on the treatment modalities available for CDI in cancer patients. Relevant articles highlighting therapeutic and symptomatic management of CDI patients with underlying malignancy have been summarized.
Despite the current options available, more studies are needed to assess the newer therapeutic options that are being employed for populations other than cancer patients.
艰难梭菌感染（CDI）是一个重大的健康负担，现在被认为是接受抗生素治疗的患者获得性腹泻的主要原因。这种病原体感染的并发症包括严重腹泻，导致电解质失衡、脱水、血流动力学不稳定、中毒性巨结肠、休克和死亡。因此，了解这种感染的治疗方法非常重要，特别是在癌症患者中。
本文对癌症患者中 CDI 的治疗方法进行了深入的文献回顾。总结了突出治疗和症状管理的相关文章，以帮助癌症合并艰难梭菌感染的患者。
尽管目前有多种治疗选择，但仍需要更多的研究来评估除癌症患者以外的其他人群使用的新的治疗选择。
